Potentia
General Data
Reg Number
516562196
Sector
Biomed
Established
2022
No. of Employees
5
Stage
R&D
Additional Funding
0
Description
Potentia Ltd is developing an innovative Antibody Oligo Conjugate (AOC), platform for treatment of Peripheral Nerve System (PNS) diseases, and is focusing on Charcot-Marie-Tooth 1A (CMT1A) as its first indication.
Technology
Medtech, biotechnology.
Targeted Customers
Physicians, focusing on Charcot–Marie–Tooth disease.
Management personnel
Barak Azmon - CEO & Co-Founder
Winning details
Route name
Winning year
Technological Innovation Incubators Program – 2020 – Incubators Fund
Technological Innovation Incubators Program – 2020 – Incubators Fund
2026